🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Merci Fabrice Barlesi pour ta très belle conférence sur les mécanismes de résistance à l’immunothérapie au cours de la réunion plénière du GFPC à Marseille ! Pascale Tomasini

🚨Our RWE #perioperative #NSCLC study now in JAMA Network Open study of 1334 pts with stage II–IIIA resectable NSCLC: ◼️Neoadj DMFS @ 18 mo: 80% ◼️Adj DMFS @ 18 mo: 83 % ◼️Uptake was low: <30% ◼️Favorable outcomes, but time to expand access OncoAlert bit.ly/3I5Aeck

1/3 🫁 #TTF-1 is a new marker to identify patients best suited for #lung cancer KRAS inhibitors 🫁 🫁 #Sotorasib - #KRAS G12C mut 🫁 🌟 #Lung cancer patients with high #TTF-1 expression had improved survival outcomes after treatment with the #KRAS inhibitor #Sotrasib.

🔬Pour une recherche sur échantillons biologiques humains française libérée des freins administratifs inutiles ➡️Un enjeu crucial pour l’innovation médicale en France 👉Déjà plus de 490 signataires : app.evalandgo.com/f/285125/4q5DU… #innovation #santé #CODECOH #RechercheClinique

#SCLC: Practice-changing ASCO data. IMforte shows lurbinectedin + atezo maintenance improves PFS, OS & QoL — but toxicity management is key. How are you discussing tradeoffs with patients? bit.ly/44PL4ft #LungCancer #ASCO25 Eric K. Singhi, MD Sandip Patel MD FASCO

Single-Agent Divarasib in Patients With KRAS G12C–Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study |Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. Co-authored by @conorsteuermd Read the full article. brnw.ch/21wU4uz

Félicitations au Pr Alexis Cortot Alexis_Cortot , élu Président de l'IFCT (2025-2027), ainsi qu'aux membres élus au Conseil d'Administration de l'IFCT. Merci au Pr Westeel & aux membres sortants pour leur implication dans l’essor de notre intergroupe : ifct.fr/component/acym…

Interesting phase II trial JTO & JTO CRR using ctDNA (tumor informed) dynamics as early predictor of response to pembrolizumab monotherapy for NSCLC. Drop in VAF by at least 3-fold predicted PR/PD and correlated well with PFS and OS. jtocrr.org/article/S2666-…

Christophe André, philosophe, psychiatre et écrivain vous invite à participer au 1er Colloque "INSPIRE à pleins poumons" organisé par l'association ALK ROS1 France Cancer Poumon : programme : ALK_programme_WEB

🎉Out now! "Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?" in JCO Oncology Practice💉 #SC delivery means less chair time for patients & more efficient clinics! But there are financial hurdles we need to tackle. 🔗bit.ly/455GyJQ

CROWN makes a strong case for 1L lorlatinib. How can patients manage side effects? This new guide, co-authored by our VP Nancee Pronsati & Ken Culver w Ben Solomon, Tony Mok, Stephen V Liu, MD Julien Mazieres & other experts, provides practical solutions. 👇 sciencedirect.com/science/articl…

In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intracranial activity.In this review, we discuss these topics. Is time to redefine doses of TT as now applied across stages? doi.org/10.1016/j.ctrv…

Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR & platinum therapy. In this episode of #LungCancerConsidered, Narjust Florez, MD, FASCO and Jacob sands break down the data and clinical implications of this exciting development. 🎧

What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…

Big news for the ALK+ community! 🚀 Nuvalent has kicked off the Phase 3 ALKAZAR trial to test neladalkib (NVL‑655) vs. alectinib for newly diagnosed ALK+ #lungcancer. More options in the first-line setting bring more hope. More info 👉 investors.nuvalent.com/2025-07-21-Nuv… #LCSM

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis in ESMO Open. 229 pts, 169 treated with 1st line Tx, 68.6% PD-L1 high, 39.7% KRAS mut. Longer PFS and OS with ICIs+/-CT as compared to CT alone. esmoopen.com/article/S2059-…

Exploration of weight gain associated with TKIs for driver-positive NSCLC JTO & JTO CRR. Highest risk associated with lorlatinib (36%), alectinib (15%), crizotinib (5%), lowest with osimertinib and erlotinib. Important to monitor risk over time, management. jtocrr.org/article/S2666-…

Phase I results of obrixtamig (DLL3-CD3 bispecific T-cell engager) Journal of Clinical Oncology (n=168 SCLC / neuroendocrine carcinoma). Across doses/cohorts, RR 23%, DOR 8.5m (in large cell neuroendocrine, RR 70%). CRS in 57% (G3+ 3%). Active challenger to tarlatamab. ascopubs.org/doi/10.1200/JC…